Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Can open-label studies demonstrate efficacy in improving sexual function?

International Journal of Impotence Research volume 21, page 265 (2009)Cite this article

In a recent paper in the Journal Chung et al. report effects of the α1-adrenoceptor antagonist alfuzosin on sexual function when used in the open-label treatment of 148 males with voiding dysfunction.1 Key findings of the trial include a statistically significant improvement of voiding symptoms (assessed by the International Prostate Symptom Score and free flow Qmax), as well as Male Sexual Health Questionnaire (MSHQ) and two of its three domains (satisfaction domain not significantly improved) or the International Index of Erectile Function (IIEF) when compared with baseline values. The authors conclude that alfuzosin is ‘effective in improving sexual function’ in the treatment of patients with benign prostatic hyperplasia.

Although the findings on voiding symptoms confirm the results from many placebo-controlled double-blind studies,2 to the best of our knowledge there is no earlier study showing benefits of alfuzosin over placebo on sexual function under double blind conditions.3 Double-blind comparative studies also failed to show significant benefits of alfuzosin over other α1-adrenoceptor antagonists with regard to sexual function.4

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chung BH, Lee J-Y, Kim C-I, Kim C-S, Oh C-Y, Lee S-W et al. Sexuality and the management of BPH with alfuzosin (SAMBA) trial. Int J Impot Res 2009; 21: 68–73.

    Article  Google Scholar 

  2. Milani S, Djavan B . Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on a1-adrenoceptor antagonists. BJU Int 2005; 95 (Suppl. 4): 29–36.

    Article  CAS  Google Scholar 

  3. van Dijk MM, de la Rosette JJMCH, Michel MC . Effects of a1-adrenoceptor antagonists on male sexual function. Drugs 2006; 66: 287–301.

    Article  CAS  Google Scholar 

  4. Nordling J . Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005; 95: 1006–1012.

    Article  CAS  Google Scholar 

  5. Höfner K, Claes H, de Reijke TM, Folkestad B, Speakman MJ . Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335–341.

    Article  Google Scholar 

  6. Rosen RC, Seftel AD . Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link. Int J Impot Res 2008; 20 (Suppl 3): S27–S32.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Pharmacotherapy, Academic Medical Center, Meibergdreef 15, Amsterdam, The Netherlands

    M C Michel

  2. Department of Urology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, Amsterdam, The Netherlands

    A Meissner

Authors
  1. M C Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Meissner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M C Michel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michel, M., Meissner, A. Can open-label studies demonstrate efficacy in improving sexual function?. Int J Impot Res 21, 265 (2009). https://doi.org/10.1038/ijir.2009.12

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2009.12

Search

Advanced search

Quick links